Alzheimer and Parkinson’s disease are the most common neurodegenerative disorders. As people are getting older than in previous generations, the number of people who are affected has increased. Unfortunately, there is no cure for these diseases. The currently prescribed drugs only delay the disease progression for a short while. There is clearly a high need to bring new and effective treatments to the market.

Surprisingly, diabetes is one of the risk factors for Alzheimer and Parkinson’s disease. The link between these conditions seems to be that insulin is losing its effect in the brains of people with Alzheimer or Parkinson’s. Insulin not only regulated blood sugar levels, but also activates cell growth and repair mechanisms. With failing cell repair, neurons are vulnerable to attack and damage that accumulates over time. Neurons are not being replaced in our brains and have to last us a lifetime.

The observation that diabetes is a risk factor lead us to investigate if drugs that are used to treat diabetes may also affect the brain and reduce the risk of developing Alzheimer and Parkinson’s disease. In a series of experiments, my group could show that this is indeed the case. Some drugs currently on the market show promise of genuinely stopping the disease progression.

Several clinical trials that test such drugs in people with Alzheimer or Parkinson’s disease have started now. A pilot study led by a team in London has already shown good effects in Parkinson’s patients. In another pilot study in people with Alzheimer’s disease conducted in Denmark, brain imaging showed that the progression of the disease was halted. These first very encouraging results show that we are on the right track. The trials show that the failure of insulin to do its job in the brain is treated effectively by the diabetes drugs.

There are ongoing larger clinical trials to analyse in more details what the changes are and how well the drugs protect the brain from degeneration. Furthermore, we need to find out if the drugs are still effective in people who are already advanced in the disease progression.

Christian Holscher,
Division of Biomedical and Life Sciences
Faculty of Health and Medicine
Furness college, B65
Lancaster, UK

In any case, we are confident that the novel treatments are making a genuine difference, and are protecting the brain rather than just mask the symptoms. This is excellent news and opens up the possibility of stopping these diseases all together. Thanks to the generous support of charities such as the Alzheimer’s Society UK or the Cure Parkinson’s Trust, we can test these promising drugs in larger trials. As the drugs in question are already on the market, we know a lot about them and how they work. We know that they are safe and are effective. There is no need for extensive toxicology tests. This saves several years and a lot of money, and makes it possible to get FDA approval much faster.

The first drug trial in Parkinson’s disease will report in April 2016, and an ongoing clinical trial in Alzheimer’s disease should be finished at the end of 2016. If these trials show clear effects, and we are confident that they will, we finally have a new generation of drug treatments that will start a new chapter in the treatment of both Alzheimer and Parkinson’s disease. It has been a long time coming, but good things come to those who wait.

Publication

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease.
Liu W, Jalewa J, Sharma M, Li G, Li L, Hölscher C
Neuroscience. 2015 Sep 10

Read offline:     

Related Articles:

	Inhibition of bovine insulin amyloid fibrillation and… The misfolding and subsequent aggregation into β-sheet rich assemblies of endogenous polypeptides, such as β-amyloid peptide, tau protein, α-synuclein, and insulin are the underlying causes of diabetes and many neurodegenerative…
	Nutritional strategies in managing postmeal glucose for Type… The postmeal hyperglycemia is a common feature of Type 2 Diabetes (T2D) with the majority of the patients have not achieved the postmeal target of less than 7.8 mmol/L at…
	Can tremor, depression and progression of the Parkinson’s… The short answer to this question is YES! Parkinson’s disease (PD) is the second most common age-related and progressive neurodegenerative disorder following Alzheimer’s disease (AD). It is associated with motor…
	Reprogramming skin into brain to study aging and age-related… “Inevitable as the passing of time” is a common phrase and a simple truth; in our lives, we may have impactful experiences, grow and learn but, inescapably, we age. It…
	Metformin improves pancreatic cancer and lymphoma outcomes… Type 2 diabetics are at increased risk of cancer in part because of increased insulin in the blood from insulin resistance. Insulin and its related growth factor IGF-1 can stimulate…
	2-in-1: A new strategy against Parkinson´s Disease Parkinson´s disease is a neurological disorder, which affects around 6 mio people worldwide, a number being expected to double within the next 20 years. It is characterized by a progressive…